ALB and rheumatoid arthritis: Ozoralizumab, a bispecific therapy in active Phase-III clinical trials for rheumatoid arthritis, has a VH(TNFA)–VH(ALB)–VH(TNFA) configuration, where VH(TNFA) is a heavy chain designed to bind to TNF-α, and VH(ALB) is another heavy chain designed to bind ALB.